New therapeutic approach prevents the growth of metastatic tumors by forcing cancer cells into a dormant state where they can't proliferate.

Cancer occurs when cells grow uncontrollably and spread to other organs in the body. Cancer cells differ from normal cells in many ways.

Scientists tested venom from more than 300 honeybees and bumblebees against two types of aggressive, hard to treat breast cancer.

The revolutionary new drug avoids the appearance of metastases in 80% and local recurrences of human breast cancer in 75% of cases.

A global study led by the University of Otago has discovered a gene, that when modified, could reduce the risk of breast cancer.

One characteristic of cancer cells is their high adaptability to different environments in the body and to drug treatments.

AI can assist in making or verifying a diagnosis, it can help match the treatment to the individual patient, it can offer a prognosis.

Researchers have determined that biomarkers known as microRNAs can predict which patients with breast cancer are likely to face recurrence.

The most aggressive triple negative breast cancer affects 1,000 patients per year in Belgium, while the figure worldwide is 225,000.

Researchers have tested the possibility of artificially maturing breast cancer cells as an approach to turn them into a more normal cell.

MicroRNA (miRNA) can be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality.

The European honeybee (Apis mellifera) has been the source of a number of products used medicinally by humans, such as honey and venom.

Triple negative breast cancer accounts for 10 to 15% of all breast cancers and affects 225,000 patients per year worldwide.

In a new way to treat triple-negative breast cancer, researchers have differentiated cancer cells to convert them into less harmful cells.

The cancer community is buzzing over a new study that says venom from bees can kill cancer cells within one hour of exposure.

When detected early, some cancers are more aggressive and fatal than others. This is the case, with triple negative breast cancer.

A drug developed for diseases other than cancer, MitoQ, avoids the appearance of metastases in 80% and local recurrences.

The technique combines ultrasound with tumor-targeted microbubbles. Once activated, the microbubbles explode like smart warheads.

Researchers found MitoQ avoids the appearance of metastases in 80% and local recurrences of human breast cancer in 75% of cases.

Delivering a targeted immunotoxin into breast ducts via openings in the nipple wiped out all visible and invisible precancerous lesions